Trials / Terminated
TerminatedNCT01823679
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell carcinoma of the skin.
Detailed description
Participants are to receive 500 mg/m² of capecitabine orally (PO) twice daily (BID) on days 1 to 14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | Given orally |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2013-04-04
- Last updated
- 2018-04-12
- Results posted
- 2017-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01823679. Inclusion in this directory is not an endorsement.